Azilsartan (Edarbi): a new ARB for treating hypertension

Azilsartan medoxomil (Edarbi) is a new angiotensin-II receptor blocker for use in the treatment of hypertension. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Gordon McInnes discusses its place in treatment.

Azilsartan Edarbi a new ARB for treating hypertension

Add yours ↓
Web design and marketing agency Leamington Spa